1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Macular Degeneration 1.2.3 Diabetic Macular Edema 1.2.4 Diabetic Retinopathy(DR) 1.2.5 Retinal Vein Occlusion 1.2.6 Wet Age-Related Macular Degeneration (wAMD) 1.2.7 Dry Age-Related Macular Degeneration (dAMD) 1.2.8 Other 1.3 Market by Application 1.3.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Other 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Perspective (2017-2028) 2.2 Macular Degeneration (AMD) and Other Retinal Diseases Growth Trends by Region 2.2.1 Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Region (2017-2022) 2.2.3 Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Region (2023-2028) 2.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Dynamics 2.3.1 Macular Degeneration (AMD) and Other Retinal Diseases Industry Trends 2.3.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Drivers 2.3.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Challenges 2.3.4 Macular Degeneration (AMD) and Other Retinal Diseases Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue 3.1.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue (2017-2022) 3.1.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Players (2017-2022) 3.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Macular Degeneration (AMD) and Other Retinal Diseases Revenue 3.4 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio 3.4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration (AMD) and Other Retinal Diseases Revenue in 2021 3.5 Macular Degeneration (AMD) and Other Retinal Diseases Key Players Head office and Area Served 3.6 Key Players Macular Degeneration (AMD) and Other Retinal Diseases Product Solution and Service 3.7 Date of Enter into Macular Degeneration (AMD) and Other Retinal Diseases Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Type 4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Type (2017-2022) 4.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Type (2023-2028) 5 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Application 5.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Application (2017-2022) 5.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028) 6.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) 6.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028) 7.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) 7.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028) 8.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) 8.3 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028) 9.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) 9.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028) 10.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) 10.3 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 Regeneron Pharmaceuticals 11.1.1 Regeneron Pharmaceuticals Company Detail 11.1.2 Regeneron Pharmaceuticals Business Overview 11.1.3 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.1.4 Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.1.5 Regeneron Pharmaceuticals Recent Development 11.2 Bayer HealthCare 11.2.1 Bayer HealthCare Company Detail 11.2.2 Bayer HealthCare Business Overview 11.2.3 Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.2.4 Bayer HealthCare Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.2.5 Bayer HealthCare Recent Development 11.3 Novartis 11.3.1 Novartis Company Detail 11.3.2 Novartis Business Overview 11.3.3 Novartis Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.3.4 Novartis Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.3.5 Novartis Recent Development 11.4 Roche 11.4.1 Roche Company Detail 11.4.2 Roche Business Overview 11.4.3 Roche Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.4.4 Roche Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.4.5 Roche Recent Development 11.5 Kanghong Pharma 11.5.1 Kanghong Pharma Company Detail 11.5.2 Kanghong Pharma Business Overview 11.5.3 Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.5.4 Kanghong Pharma Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.5.5 Kanghong Pharma Recent Development 11.6 Merck 11.6.1 Merck Company Detail 11.6.2 Merck Business Overview 11.6.3 Merck Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.6.4 Merck Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.6.5 Merck Recent Development 11.7 Allergan 11.7.1 Allergan Company Detail 11.7.2 Allergan Business Overview 11.7.3 Allergan Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.7.4 Allergan Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.7.5 Allergan Recent Development 11.8 Santen Pharmaceutical 11.8.1 Santen Pharmaceutical Company Detail 11.8.2 Santen Pharmaceutical Business Overview 11.8.3 Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.8.4 Santen Pharmaceutical Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.8.5 Santen Pharmaceutical Recent Development 11.9 GlaxoSmithKline Pharmaceuticals 11.9.1 GlaxoSmithKline Pharmaceuticals Company Detail 11.9.2 GlaxoSmithKline Pharmaceuticals Business Overview 11.9.3 GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.9.4 GlaxoSmithKline Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.9.5 GlaxoSmithKline Pharmaceuticals Recent Development 11.10 Pfizer 11.10.1 Pfizer Company Detail 11.10.2 Pfizer Business Overview 11.10.3 Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.10.4 Pfizer Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.10.5 Pfizer Recent Development 11.11 Acucela 11.11.1 Acucela Company Detail 11.11.2 Acucela Business Overview 11.11.3 Acucela Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.11.4 Acucela Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.11.5 Acucela Recent Development 11.12 Valent Pharmaceuticals 11.12.1 Valent Pharmaceuticals Company Detail 11.12.2 Valent Pharmaceuticals Business Overview 11.12.3 Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.12.4 Valent Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.12.5 Valent Pharmaceuticals Recent Development 11.13 IVERIC 11.13.1 IVERIC Company Detail 11.13.2 IVERIC Business Overview 11.13.3 IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.13.4 IVERIC Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.13.5 IVERIC Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Macular Degeneration Table 3. Key Players of Diabetic Macular Edema Table 4. Key Players of Diabetic Retinopathy(DR) Table 5. Key Players of Retinal Vein Occlusion Table 6. Key Players of Wet Age-Related Macular Degeneration (wAMD) Table 7. Key Players of Dry Age-Related Macular Degeneration (dAMD) Table 8. Key Players of Other Table 9. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 10. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 11. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2017-2022) & (US$ Million) Table 12. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region (2017-2022) Table 13. Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 14. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region (2023-2028) Table 15. Macular Degeneration (AMD) and Other Retinal Diseases Market Trends Table 16. Macular Degeneration (AMD) and Other Retinal Diseases Market Drivers Table 17. Macular Degeneration (AMD) and Other Retinal Diseases Market Challenges Table 18. Macular Degeneration (AMD) and Other Retinal Diseases Market Restraints Table 19. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Players (2017-2022) & (US$ Million) Table 20. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Players (2017-2022) Table 21. Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration (AMD) and Other Retinal Diseases as of 2021) Table 22. Ranking of Global Top Macular Degeneration (AMD) and Other Retinal Diseases Companies by Revenue (US$ Million) in 2021 Table 23. Global 5 Largest Players Market Share by Macular Degeneration (AMD) and Other Retinal Diseases Revenue (CR5 and HHI) & (2017-2022) Table 24. Key Players Headquarters and Area Served Table 25. Key Players Macular Degeneration (AMD) and Other Retinal Diseases Product Solution and Service Table 26. Date of Enter into Macular Degeneration (AMD) and Other Retinal Diseases Market Table 27. Mergers & Acquisitions, Expansion Plans Table 28. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2017-2022) & (US$ Million) Table 29. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type (2017-2022) Table 30. Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 31. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type (2023-2028) Table 32. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2017-2022) & (US$ Million) Table 33. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Application (2017-2022) Table 34. Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 35. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Application (2023-2028) Table 36. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) & (US$ Million) Table 37. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) & (US$ Million) Table 38. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) & (US$ Million) Table 39. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) & (US$ Million) Table 40. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2017-2022) & (US$ Million) Table 41. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2023-2028) & (US$ Million) Table 42. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) & (US$ Million) Table 43. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) & (US$ Million) Table 44. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) & (US$ Million) Table 45. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) & (US$ Million) Table 46. Regeneron Pharmaceuticals Company Detail Table 47. Regeneron Pharmaceuticals Business Overview Table 48. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product Table 49. Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 50. Regeneron Pharmaceuticals Recent Development Table 51. Bayer HealthCare Company Detail Table 52. Bayer HealthCare Business Overview Table 53. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Product Table 54. Bayer HealthCare Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 55. Bayer HealthCare Recent Development Table 56. Novartis Company Detail Table 57. Novartis Business Overview Table 58. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Product Table 59. Novartis Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 60. Novartis Recent Development Table 61. Roche Company Detail Table 62. Roche Business Overview Table 63. Roche Macular Degeneration (AMD) and Other Retinal Diseases Product Table 64. Roche Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 65. Roche Recent Development Table 66. Kanghong Pharma Company Detail Table 67. Kanghong Pharma Business Overview Table 68. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Product Table 69. Kanghong Pharma Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 70. Kanghong Pharma Recent Development Table 71. Merck Company Detail Table 72. Merck Business Overview Table 73. Merck Macular Degeneration (AMD) and Other Retinal Diseases Product Table 74. Merck Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 75. Merck Recent Development Table 76. Allergan Company Detail Table 77. Allergan Business Overview Table 78. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Product Table 79. Allergan Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 80. Allergan Recent Development Table 81. Santen Pharmaceutical Company Detail Table 82. Santen Pharmaceutical Business Overview Table 83. Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Product Table 84. Santen Pharmaceutical Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 85. Santen Pharmaceutical Recent Development Table 86. GlaxoSmithKline Pharmaceuticals Company Detail Table 87. GlaxoSmithKline Pharmaceuticals Business Overview Table 88. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product Table 89. GlaxoSmithKline Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 90. GlaxoSmithKline Pharmaceuticals Recent Development Table 91. Pfizer Company Detail Table 92. Pfizer Business Overview Table 93. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Product Table 94. Pfizer Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 95. Pfizer Recent Development Table 96. Acucela Company Detail Table 97. Acucela Business Overview Table 98. Acucela Macular Degeneration (AMD) and Other Retinal DiseasesProduct Table 99. Acucela Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 100. Acucela Recent Development Table 101. Valent Pharmaceuticals Company Detail Table 102. Valent Pharmaceuticals Business Overview Table 103. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal DiseasesProduct Table 104. Valent Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 105. Valent Pharmaceuticals Recent Development Table 106. IVERIC Company Detail Table 107. IVERIC Business Overview Table 108. IVERIC Macular Degeneration (AMD) and Other Retinal DiseasesProduct Table 109. IVERIC Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) & (US$ Million) Table 110. IVERIC Recent Development Table 111. Research Programs/Design for This Report Table 112. Key Data Information from Secondary Sources Table 113. Key Data Information from Primary Sources List of Figures Figure 1. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type: 2021 VS 2028 Figure 2. Macular Degeneration Features Figure 3. Diabetic Macular Edema Features Figure 4. Diabetic Retinopathy(DR) Features Figure 5. Retinal Vein Occlusion Features Figure 6. Wet Age-Related Macular Degeneration (wAMD) Features Figure 7. Dry Age-Related Macular Degeneration (dAMD) Features Figure 8. Other Features Figure 9. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application in 2021 & 2028 Figure 10. Hospital Case Studies Figure 11. Clinic Case Studies Figure 12. Other Case Studies Figure 13. Macular Degeneration (AMD) and Other Retinal Diseases Report Years Considered Figure 14. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 15. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 16. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region: 2021 VS 2028 Figure 17. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Players in 2021 Figure 18. Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration (AMD) and Other Retinal Diseases as of 2021) Figure 19. The Top 10 and 5 Players Market Share by Macular Degeneration (AMD) and Other Retinal Diseases Revenue in 2021 Figure 20. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2017-2028) Figure 22. United States Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Canada Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2017-2028) Figure 26. Germany Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. France Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. U.K. Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Italy Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Russia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Nordic Countries Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region (2017-2028) Figure 34. China Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. South Korea Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. India Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Australia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2017-2028) Figure 42. Mexico Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Brazil Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 44. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2017-2028) Figure 46. Turkey Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 47. Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2017-2028) & (US$ Million) Figure 48. Regeneron Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 49. Bayer HealthCare Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 50. Novartis Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 51. Roche Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 52. Kanghong Pharma Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 53. Merck Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 54. Allergan Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 55. Santen Pharmaceutical Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 56. GlaxoSmithKline Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 57. Pfizer Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 58. Acucela Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 59. Valent Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 60. IVERIC Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) Figure 61. Bottom-up and Top-down Approaches for This Report Figure 62. Data Triangulation Figure 63. Key Executives Interviewed

Regeneron Pharmaceuticals Bayer HealthCare Novartis Roche Kanghong Pharma Merck Allergan Santen Pharmaceutical GlaxoSmithKline Pharmaceuticals Pfizer Acucela Valent Pharmaceuticals IVERIC